MX2015014851A - Vacuna de adn que dirige wt-1 novedosa para inmunoterapia del cancer. - Google Patents
Vacuna de adn que dirige wt-1 novedosa para inmunoterapia del cancer.Info
- Publication number
- MX2015014851A MX2015014851A MX2015014851A MX2015014851A MX2015014851A MX 2015014851 A MX2015014851 A MX 2015014851A MX 2015014851 A MX2015014851 A MX 2015014851A MX 2015014851 A MX2015014851 A MX 2015014851A MX 2015014851 A MX2015014851 A MX 2015014851A
- Authority
- MX
- Mexico
- Prior art keywords
- salmonella
- cancer immunotherapy
- based vectors
- tumor gene
- immunotherapy targeting
- Prior art date
Links
- 241000607142 Salmonella Species 0.000 title abstract 3
- 238000002619 cancer immunotherapy Methods 0.000 title abstract 2
- 108700025700 Wilms Tumor Genes Proteins 0.000 title 1
- 230000008685 targeting Effects 0.000 title 1
- 239000013598 vector Substances 0.000 title 1
- 230000002238 attenuated effect Effects 0.000 abstract 2
- 102000053602 DNA Human genes 0.000 abstract 1
- 108020004511 Recombinant DNA Proteins 0.000 abstract 1
- 208000008383 Wilms tumor Diseases 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K2035/11—Medicinal preparations comprising living procariotic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/42—Salmonella
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Engineering & Computer Science (AREA)
- Virology (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención se refiere a una cepa mutante atenuada de Salmonella que comprende una molécula de ADN recombinante que codifica la proteína del tumor de Wilms 1. En particular, la presente invención se refiere al uso de dicha cepa mutante atenuada de Salmonella en la inmunoterapia del cáncer.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP13002245 | 2013-04-25 | ||
PCT/EP2014/001099 WO2014173542A1 (en) | 2013-04-25 | 2014-04-24 | Salmonella-based vectors for cancer immunotherapy targeting wilms' tumor gene wt1 |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2015014851A true MX2015014851A (es) | 2016-03-09 |
MX364922B MX364922B (es) | 2019-05-14 |
Family
ID=48190068
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2015014851A MX364922B (es) | 2013-04-25 | 2014-04-24 | Vacuna de adn que dirige wt-1 novedosa para inmunoterapia contra cáncer. |
Country Status (15)
Country | Link |
---|---|
US (2) | US9920297B2 (es) |
EP (1) | EP2988762B1 (es) |
JP (1) | JP6416877B2 (es) |
CN (1) | CN105246496A (es) |
AU (1) | AU2014256457B2 (es) |
CA (1) | CA2910213A1 (es) |
DK (1) | DK2988762T3 (es) |
ES (1) | ES2675020T3 (es) |
HU (1) | HUE038861T2 (es) |
LT (1) | LT2988762T (es) |
MX (1) | MX364922B (es) |
PL (1) | PL2988762T3 (es) |
SG (1) | SG11201508521SA (es) |
SI (1) | SI2988762T1 (es) |
WO (1) | WO2014173542A1 (es) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2565201B1 (en) | 2005-10-17 | 2014-11-26 | Sloan-Kettering Institute For Cancer Research | WT1 HLA class II-binding peptides and compositions and methods comprising same |
CA2645766A1 (en) | 2006-04-10 | 2007-10-25 | Sloan Kettering Institute For Cancer Research | Immunogenic wt-1 peptides and methods of use thereof |
CN104684577B (zh) | 2012-01-13 | 2018-05-08 | 纪念斯隆凯特林癌症中心 | 免疫原性wt-1肽及其使用方法 |
PT2945647T (pt) | 2013-01-15 | 2020-11-26 | Memorial Sloan Kettering Cancer Center | Péptidos imunogénicos wt-1 e métodos de uso dos mesmos |
US10815273B2 (en) | 2013-01-15 | 2020-10-27 | Memorial Sloan Kettering Cancer Center | Immunogenic WT-1 peptides and methods of use thereof |
HUE038861T2 (hu) * | 2013-04-25 | 2018-12-28 | Vaximm Ag | Salmonella-alapú vektorok Wilms-tumor WZ1 gént célzó rák immunterápiához |
AU2014365900B2 (en) | 2013-12-18 | 2020-04-09 | Vaximm Gmbh | Novel MSLN targeting DNA vaccine for cancer immunotherapy |
US20180153976A1 (en) | 2015-06-18 | 2018-06-07 | Vaximm Ag | Novel cmv pp65 targeting dna vaccine for cancer immunotherapy |
DK3310379T3 (da) * | 2015-06-18 | 2019-12-16 | Vaximm Ag | Vegfr-2-targeterende dna-vaccine til kombinationsterapi |
JP6770269B2 (ja) * | 2015-06-25 | 2020-10-14 | 国立大学法人神戸大学 | 経口腫瘍ワクチン |
EP3484503A1 (en) | 2016-07-13 | 2019-05-22 | Vaximm AG | Process for the production of a dna vaccine for cancer immunotherapy |
BR112019009003A2 (pt) * | 2016-11-04 | 2019-07-16 | Vaximm Ag | cepa atenuada de salmonela e composição farmacêutica |
EP3583200A1 (en) * | 2017-02-17 | 2019-12-25 | Vaximm AG | Novel vegfr-2 targeting immunotherapy approach |
SG11201908528UA (en) * | 2017-03-17 | 2019-10-30 | Vaximm Ag | Novel pd-l1 targeting dna vaccine for cancer immunotherapy |
US20210213121A1 (en) * | 2018-09-05 | 2021-07-15 | Vaximm Ag | Neoantigen targeting dna vaccine for combination therapy |
CN114980871A (zh) | 2020-01-13 | 2022-08-30 | 万科斯蒙股份有限公司 | 基于沙门氏菌的dna疫苗联合抗生素 |
CN111647066B (zh) * | 2020-07-01 | 2020-12-18 | 维肽瀛(上海)生物技术有限公司 | Wt1多肽肿瘤抑制剂 |
CA3238816A1 (en) * | 2021-12-09 | 2023-06-15 | Prokarium Limited | Combination cancer therapy |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5726288A (en) * | 1989-11-13 | 1998-03-10 | Massachusetts Institute Of Technology | Localization and characterization of the Wilms' tumor gene |
ATE309378T1 (de) * | 1997-04-18 | 2005-11-15 | Biotechnolog Forschung Gmbh | Abgeschwächter salmonellenstamm, gebraucht als vehikel zur oralen immunisierung |
CN1859851A (zh) | 2002-07-12 | 2006-11-08 | 约翰斯霍普金斯大学 | 间皮素疫苗与模型系统 |
WO2004006837A2 (en) | 2002-07-12 | 2004-01-22 | The Johns Hopkins University | Mesothelin vaccines and model systems |
US9200036B2 (en) | 2002-07-12 | 2015-12-01 | The Johns Hopkins University | Mesothelin vaccines and model systems |
CN101115766B (zh) * | 2004-06-18 | 2013-05-08 | 印度免疫有限公司 | 用于抗人乳头瘤病毒型16的salmonella疫苗菌株的密码子经优化的hpv16l1 |
WO2006137836A2 (en) * | 2004-08-17 | 2006-12-28 | Research Development Foundation | Bacterial vector systems |
CA2601187A1 (en) * | 2005-03-09 | 2006-09-14 | Board Of Regents, The University Of Texas System | Novel htmc promoter and vectors for the tumor-selective and high-efficient expression of cancer therapeutic genes |
EP2565201B1 (en) * | 2005-10-17 | 2014-11-26 | Sloan-Kettering Institute For Cancer Research | WT1 HLA class II-binding peptides and compositions and methods comprising same |
US7935804B2 (en) | 2006-03-01 | 2011-05-03 | Aduro Biotech | Engineered Listeria and methods of use thereof |
EP1921149A1 (en) * | 2006-11-13 | 2008-05-14 | AEterna Zentaris GmbH | Microorganisms as carriers of nucleotide sequences coding for antigens and protein toxins, process of manufacturing and uses thereof |
WO2012149364A1 (en) * | 2011-04-28 | 2012-11-01 | Diamond Don J | Tumor associated vaccines and compositions for disrupting tumor-derived immunosuppression for use in combination cancer immunotherapy |
EP2895596A4 (en) * | 2012-09-17 | 2016-07-27 | Us Health | ORAL MULTIFUNCTION VACCINE BASED ON CHROMOSOME RECOMBINEERING |
HUE038861T2 (hu) | 2013-04-25 | 2018-12-28 | Vaximm Ag | Salmonella-alapú vektorok Wilms-tumor WZ1 gént célzó rák immunterápiához |
AU2014365900B2 (en) * | 2013-12-18 | 2020-04-09 | Vaximm Gmbh | Novel MSLN targeting DNA vaccine for cancer immunotherapy |
-
2014
- 2014-04-24 HU HUE14721208A patent/HUE038861T2/hu unknown
- 2014-04-24 DK DK14721208.8T patent/DK2988762T3/en active
- 2014-04-24 CN CN201480023775.9A patent/CN105246496A/zh active Pending
- 2014-04-24 SG SG11201508521SA patent/SG11201508521SA/en unknown
- 2014-04-24 ES ES14721208.8T patent/ES2675020T3/es active Active
- 2014-04-24 SI SI201430778T patent/SI2988762T1/sl unknown
- 2014-04-24 EP EP14721208.8A patent/EP2988762B1/en active Active
- 2014-04-24 LT LTEP14721208.8T patent/LT2988762T/lt unknown
- 2014-04-24 CA CA2910213A patent/CA2910213A1/en not_active Abandoned
- 2014-04-24 MX MX2015014851A patent/MX364922B/es active IP Right Grant
- 2014-04-24 WO PCT/EP2014/001099 patent/WO2014173542A1/en active Application Filing
- 2014-04-24 US US14/786,652 patent/US9920297B2/en active Active
- 2014-04-24 AU AU2014256457A patent/AU2014256457B2/en not_active Ceased
- 2014-04-24 PL PL14721208T patent/PL2988762T3/pl unknown
- 2014-04-24 JP JP2016509326A patent/JP6416877B2/ja active Active
-
2018
- 2018-01-16 US US15/872,750 patent/US10815455B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
JP2016518835A (ja) | 2016-06-30 |
SI2988762T1 (sl) | 2018-10-30 |
US20180163169A1 (en) | 2018-06-14 |
AU2014256457B2 (en) | 2018-02-22 |
CN105246496A (zh) | 2016-01-13 |
MX364922B (es) | 2019-05-14 |
US10815455B2 (en) | 2020-10-27 |
ES2675020T3 (es) | 2018-07-05 |
US20160068801A1 (en) | 2016-03-10 |
US9920297B2 (en) | 2018-03-20 |
EP2988762A1 (en) | 2016-03-02 |
AU2014256457A1 (en) | 2015-11-05 |
CA2910213A1 (en) | 2014-10-30 |
HUE038861T2 (hu) | 2018-12-28 |
PL2988762T3 (pl) | 2019-01-31 |
JP6416877B2 (ja) | 2018-10-31 |
DK2988762T3 (en) | 2018-07-16 |
LT2988762T (lt) | 2018-09-25 |
SG11201508521SA (en) | 2015-11-27 |
WO2014173542A1 (en) | 2014-10-30 |
EP2988762B1 (en) | 2018-06-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX364922B (es) | Vacuna de adn que dirige wt-1 novedosa para inmunoterapia contra cáncer. | |
MX2016007939A (es) | Nueva vacuna de adn dirigida contra msln para la inmunoterapia de cancer. | |
MX2014015977A (es) | Vacuna de adn para usarse en pacientes con cancer pancreatico. | |
SA518400424B1 (ar) | جزيئات الجسم المضاد لعلاج السرطان | |
MX2015014423A (es) | Administración efectiva de genes grandes por vectores aav duales. | |
MX2018005084A (es) | Genes de ataxia de friedreich modificados y vectores para terapia genica. | |
PH12018502645A1 (en) | Optimized mini-dystrophin genes and expression cassettes and their use | |
PH12019500122A1 (en) | Bispecific antibody-like binding proteins specifically binding to cd3 and cd123 | |
MX2017014125A (es) | Variantes de alfa-amilasa y polinucleotidos que codifican las mismas. | |
MX2023004479A (es) | Sistema de vector multiple y sus usos. | |
MX2017013298A (es) | Receptores del antigeno quimerico dirigidos al antigeno de maduracion de celulas b. | |
EP3741849A3 (en) | Protease variants and polynucleotides encoding same | |
TW201613954A (en) | Interleukin-10 fusion proteins and uses thereof | |
MX2015008446A (es) | Composiciones de proteinas de union multivalentes. | |
MX371018B (es) | Polipéptidos que tienen actividad de transgalactosilación. | |
IN2014CN04586A (es) | ||
MX2013008836A (es) | Moleculas de acido nucleico que codifican novedosos antigenos de herpes, vacunas que las comprenden y metodos para su uso. | |
MX2019005272A (es) | Peptidos cancerigenos universales derivados de telomerasa. | |
NZ739133A (en) | Cellular targeted active ingredient delivery system | |
WO2013177593A3 (en) | Identification of mhc class i phospho-peptide antigens from breast cancer utilizing shla technology and complementary enrichment strategies | |
MX2015010078A (es) | Uso de polipeptidos con actividad proteasa en alimentos para animales. | |
TN2014000518A1 (en) | Reassortant btv and ahsv vaccines | |
MX2019011026A (es) | Nueva vacuna de adn dirigida a pd-l1 para inmunoterapia de cancer. | |
MX2018008797A (es) | Vacunas contra el cancer. | |
PL400718A1 (pl) | Plazmid pomocniczy, szczep i system o szerokim spektrum gospodarzy do mobilizacji plazmidów oraz ich zastosowania |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |